ArticleAME case reports2025
Pregnancy and lactation-related osteoporosis associating multiple vertebral fragility fractures treated with romosozumab: a case report.
Article in AME case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Pregnancy and lactation-associated osteoporosis: insights from an online self-reported patient survey.Archives of osteoporosis · 2026Article
- Long-Term Sequential Therapy for Pregnancy- and Lactation-Associated Osteoporosis With Multiple Vertebral Fractures: A Case Report of Over 5 Years.Case reports in obstetrics and gynecology · 2026Article
- Pregnancy and Lactation-Associated Osteoporosis: Combined Pharmacological and Rehabilitative Management.Journal of functional morphology and kinesiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pregnancy- and lactation-related osteoporosis (PLO) is a rare condition of skeletal fragility affecting women during late pregnancy and early lactation. Patients with PLO who experience multiple, rapid-onset vertebral fractures and develop kyphosis face a poorer prognosis when diagnosis and treatment are delayed. Since there is no standard treatment protocol for patients with PLO, treatment should be individually planned. Recently, romosozumab has been recognized as one of the most effective drugs for treating patients with severe osteoporosis. Because it can dramatically increase bone mineral density (BMD) in a short period in postmenopausal women with osteoporosis, it is useful for treating patients with rapidly progressive osteoporosis at a high risk of fracture. Here, we report a case of PLO associated with multiple vertebral fractures treated with romosozumab. To the best of our knowledge, this is the first report on the use of romosozumab alone for PLO. Case Description: A middle-aged postpartum and lactating woman experienced back pain at 9 months of pregnancy, which worsened after delivery. PLO was diagnosed based on multiple thoracic vertebral and sacral fragility fractures and low BMD. She was treated with romosozumab, and her back pain gradually subsided. After 12 months of romosozumab treatment, her lumbar spine BMD increased by 22.1% from baseline, and no further fractures occurred. Conclusions: Twelve months of romosozumab treatment successfully improved the clinical condition of the patient with severe PLO, resulting in a remarkable increase in BMD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.